Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non–small cell lung cancer: the …
PA Jänne, MM van den Heuvel, F Barlesi, M Cobo… - Jama, 2017 - jamanetwork.com
Importance There are no specifically approved targeted therapies for the most common
genomically defined subset of non–small cell lung cancer (NSCLC), KRAS-mutant lung
cancer. Objective To compare efficacy of the mitogen-activated protein kinase kinase (MEK)
inhibitor selumetinib+ docetaxel with docetaxel alone as a second-line therapy for
advancedKRAS-mutant NSCLC. Design, Setting, and Participants Multinational, randomized
clinical trial conducted at 202 sites across 25 countries from October 2013 through January …
genomically defined subset of non–small cell lung cancer (NSCLC), KRAS-mutant lung
cancer. Objective To compare efficacy of the mitogen-activated protein kinase kinase (MEK)
inhibitor selumetinib+ docetaxel with docetaxel alone as a second-line therapy for
advancedKRAS-mutant NSCLC. Design, Setting, and Participants Multinational, randomized
clinical trial conducted at 202 sites across 25 countries from October 2013 through January …